Biopharmaceuticals are also known as biologics. Biopharmaceutical products are pharmaceutical drugs that are synthesized, processed, or extracted from biological sources. Biopharmaceuticals include vaccines, blood products, recombinant therapeutic proteins, allergens, gene therapies, tissues and living cells used in cell therapy. Many companies outsource the manufacturing of biopharmaceuticals due to lack of manufacturing capabilities or in order to reduce the cost of manufacture process.Contract manufacturing organizations offer a wide range of services such as cell line development, process optimization, fermentation biotechnology, analytical characterization, cGMP manufacturing, and validation in each stage of clinical development and commercialization.
Major Key Players of the Biopharmaceutical Contract Manufacturing Market are:Lonza Group Ltd. (Switzerland), Boehringer Ingelheim GmbH (Germany), Charles River Laboratories, Inc. (U.S), Novartis AG (Switzerland) WuXi AppTec Group (China), Rentschler Biotechnologie GmbH (Germany), Fujifilm Holdings Corporation (Japan), Celonic AG (Switzerland), BIOMEVA GmbH (Germany), and ProBioGen AG (Germany) to name a few.
Read More @ https://www.openpr.com/news/2045100/biopharmaceutical-contract-manufacturing-market-to-witness
Major Key Players of the Biopharmaceutical Contract Manufacturing Market are:Lonza Group Ltd. (Switzerland), Boehringer Ingelheim GmbH (Germany), Charles River Laboratories, Inc. (U.S), Novartis AG (Switzerland) WuXi AppTec Group (China), Rentschler Biotechnologie GmbH (Germany), Fujifilm Holdings Corporation (Japan), Celonic AG (Switzerland), BIOMEVA GmbH (Germany), and ProBioGen AG (Germany) to name a few.
Read More @ https://www.openpr.com/news/2045100/biopharmaceutical-contract-manufacturing-market-to-witness
No comments:
Post a Comment